STOCK TITAN

Ultragenyx (RARE) awards RSUs and 79,936 stock options to officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. reported that officer Dennis Karl Huang received equity awards consisting of common stock and stock options. He was granted 23,116 shares of common stock as Restricted Stock Units (RSUs), bringing his direct common stock holdings to 147,845 shares after the award.

The RSUs were granted under the company’s 2023 Incentive Plan and vest in four equal annual installments on each anniversary of the grant date. Huang was also granted 79,936 stock options with an exercise price of $24.52 per share, expiring on April 16, 2036, which vest over four years with 1/4 vesting after one year and the remainder vesting monthly.

Positive

  • None.

Negative

  • None.
Insider Huang Dennis Karl
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 79,936 $0.00 --
Grant/Award Common Stock 23,116 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 79,936 shares (Direct, null); Common Stock — 147,845 shares (Direct, null)
Footnotes (1)
  1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
RSU grant 23,116 shares Restricted Stock Units granted on April 16, 2026
Common shares after grant 147,845 shares Direct common stock holdings following RSU award
Stock option grant 79,936 options Stock options granted on April 16, 2026
Option exercise price $24.52 per share Exercise price for 79,936 stock options
Option expiration April 16, 2036 Expiration date of granted stock options
RSU vesting schedule 4 annual installments 1/4 of RSUs vest each year over four years
Option vesting schedule 1/4 after 1 year, then monthly 1/4 vests at first anniversary; 1/48 monthly thereafter
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
vesting conditions financial
"shares of common stock underlying RSUs ... are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
exercise price financial
"conversion_or_exercise_price: 24.5200 per underlying share of Common Stock."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Huang Dennis Karl

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/16/2026A23,116(1)A$0147,845(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.5204/16/2026A79,936 (3)04/16/2036Common Stock79,936$079,936D
Explanation of Responses:
1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Remarks:
EVP, Chief Technical Operations Officer
/s/ Karah Parschauer, attorney-in-fact04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Dennis Karl Huang receive from Ultragenyx (RARE)?

Dennis Karl Huang received 23,116 Restricted Stock Units and 79,936 stock options. The RSUs are common stock awards, while the options give him the right to buy common shares at a fixed exercise price over a long-term vesting schedule.

How do the new RSUs granted to Dennis Karl Huang at Ultragenyx (RARE) vest?

The 23,116 RSUs vest in four equal annual installments. One quarter of the underlying common shares vests on each anniversary of the grant date, so the award becomes fully vested on the fourth anniversary if vesting conditions continue to be satisfied.

What are the key terms of Dennis Karl Huang’s new Ultragenyx (RARE) stock options?

Huang received 79,936 stock options with a $24.52 exercise price per share. One quarter vests on the first anniversary of the grant, and the remaining three quarters vest in equal monthly installments, with the options expiring on April 16, 2036 if not exercised earlier.

How many Ultragenyx (RARE) common shares does Dennis Karl Huang hold after these grants?

After receiving the 23,116 RSU-based common shares, Huang’s direct common stock holdings total 147,845 shares. This figure includes previously reported RSU-based shares that remain subject to vesting conditions under Ultragenyx’s equity incentive arrangements.

Are Dennis Karl Huang’s new Ultragenyx (RARE) awards open-market purchases or compensation grants?

These transactions are compensation-related grants, not open-market trades. Both the RSUs and stock options were awarded under Ultragenyx’s 2023 Incentive Plan, with a transaction code indicating grant or award acquisition rather than a discretionary market purchase or sale.